Simona Rapposelli

List of Publications by Year
in descending order

127 papers	3,359 citations	136950 32 h-index	175258 52 g-index
133 all docs	133 docs citations	133 times ranked	4650 citing authors

#	Article	IF	Citations
1	Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells. Molecules, 2022, 27, 3019.	3.8	3
2	Design, Synthesis, and In Vitro Evaluation of Novel 8-Amino-Quinoline Combined with Natural Antioxidant Acids. Pharmaceuticals, 2022, 15, 688.	3.8	2
3	Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands. Journal of Medicinal Chemistry, 2022, 65, 9918-9938.	6.4	15
4	Beyond Antioxidant Effects: Nature-Based Templates Unveil New Strategies for Neurodegenerative Diseases. Antioxidants, 2021, 10, 367.	5.1	14
5	Synthesis and pharmacological characterization of mitochondrial KATP channel openers with enhanced mitochondriotropic effects. Bioorganic Chemistry, 2021, 107, 104572.	4.1	10
6	Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis. International Journal of Molecular Sciences, 2021, 22, 3488.	4.1	5
7	Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment. Cancer Cell International, 2021, 21, 318.	4.1	139
8	Abstract 1294: Dual targeting of PDK1 and Aurora A using first-in class OXID-pyridonyl compounds in preclinical models of Ewing sarcoma. , 2021, , .		0
9	Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-20.	4.0	29
10	Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile. European Journal of Medicinal Chemistry, 2021, 226, 113895.	5.5	3
11	Editorial: Proteinâ€"Protein Interactions: Drug Discovery for the Future. Frontiers in Chemistry, 2021, 9, 811190.	3.6	9
12	Identification of a Thyroid Hormone Derivative as a Pleiotropic Agent for the Treatment of Alzheimerâ€™s Disease. Pharmaceuticals, 2021, 14, 1330.	3.8	6
13	TG68, a Novel Thyroid Hormone Receptor-Î² Agonist for the Treatment of NAFLD. International Journal of Molecular Sciences, 2021, 22, 13105.	4.1	22
14	Design, synthesis and biological evaluation of novel TRÎ² selective agonists sustained by ADME-toxicity analysis. European Journal of Medicinal Chemistry, 2020, 188, 112006.	5.5	16
15	Selective Thyroid Hormone Receptor-Beta (TRÎ²) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders. Frontiers in Medicine, 2020, 7, 331.	2.6	57
16	Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Frontiers in Pharmacology, 2020, 11, 01021.	3.5	345
17	Investigating Curcumin/Intestinal Epithelium Interaction in a Millifluidic Bioreactor. Bioengineering, 2020, 7, 100.	3.5	7
18	Potential role of two novel agonists of thyroid hormone receptor-beta on liver regeneration. Journal of Hepatology, 2020, 73, S249.	3.7	0

#	Article	IF	Citations
19	SG-2: A promising lipolytic and pro-autophagic hit-compound to treat Alzheimerâ€™s disease. Biomedical Science and Engineering, 2020, 3, .	0.0	0
20	Areca catechuâ€”From farm to food and biomedical applications. Phytotherapy Research, 2020, 34, 2140-2158.	5.8	40
21	Collecting data through high throughput inÂvitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics. Data in Brief, 2020, 29, 105206.	1.0	6
22	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopesâ€“7. Molecules, 2020, 25, 2968.	3.8	5
23	Endogenous 3-Iodothyronamine (T1AM) and Synthetic Thyronamine-Like Analog SG-2 Act as Novel Pleiotropic Neuroprotective Agents through the Modulation of SIRT6. Molecules, 2020, 25, 1054.	3.8	15
24	Potential role of two novel agonists of thyroid hormone receptorâ€Î²2 on liver regeneration. Cell Proliferation, 2020, 53, e12808.	5.3	13
25	SUN-717 SG-2 a Novel Multi-Target Directed Ligand (MTDL) for the Treatment of Neurodegenerative Diseases (NDDS). Journal of the Endocrine Society, 2020, 4, .	0.2	1
26	Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation. Cancers, 2019, 11, 1695.	3.7	4
27	Novel Dual PDK1/AurK-A Inhibitors for Cancer Therapy: Med Chem Evolution and Crystallographic Investigation. Proceedings (mdpi), 2019, 22, .	0.2	2
28	Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway. International Journal of Molecular Sciences, 2019, 20, 4054.	4.1	13
29	Design and synthesis of H2S-donor hybrids: A new treatment for Alzheimer's disease?. European Journal of Medicinal Chemistry, 2019, 184, 111745.	5.5	49
30	Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 191.	8.6	14
31	Multi-targeted ChEI-copper chelating molecules as neuroprotective agents. European Journal of Medicinal Chemistry, 2019, 174, 216-225.	5.5	18
32	A patent update on PDK1 inhibitors (2015-present). Expert Opinion on Therapeutic Patents, 2019, 29, 271-282.	5.0	18
33	Memantine prodrug as a new agent for Alzheimerâ€™s Disease. Scientific Reports, 2019, 9, 4612.	3.3	54
34	Editorial: Multi-Target-Directed Ligands (MTDL) as Challenging Research Tools in Drug Discovery: From Design to Pharmacological Evaluation. Frontiers in Chemistry, 2019, 7, 71.	3.6	34
35	Epibatidine: A Promising Natural Alkaloid in Health. Biomolecules, 2019, 9, 6.	4.0	59
36	A novel approach in glioblastoma multiforme drug discovery: perturbation studies in vitro. Journal of Applied Pharmaceutical Science, 2019, 9, 58-65.	1.0	1

#	Article	IF	Citations
37	A review on the hybrids of hydroxycinnamic acid as multi-target-directed ligands against Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2018, 26, 543-550.	3.0	67
38	Synthesis and anti-glioblastoma effects of artemisinin-isothiocyanate derivatives. RSC Advances, 2018, 8, 40974-40983.	3.6	10
39	New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective. Frontiers in Pharmacology, 2018, 9, 874.	3.5	31
40	Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4812-4816.	2.2	9
41	Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 141, 232-239.	5.5	20
42	Synthesis and Biological Evaluation of Cyclopropylamine Vitamin Dâ€Like CYP24A1 Inhibitors. ChemistrySelect, 2017, 2, 8346-8353.	1.5	2
43	A Novel H2S-releasing Amino-Bisphosphonate which combines bone anti-catabolic and anabolic functions. Scientific Reports, 2017, 7, 11940.	3.3	33
44	Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects. Journal of Medicinal Chemistry, 2017, 60, 7512-7523.	6.4	48
45	Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells. ACS Chemical Neuroscience, 2017, 8, 100-114.	3.5	45
46	Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 125, 784-792.	5.5	55
47	New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection. Frontiers in Pharmacology, 2017, 8, 905.	3.5	34
48	Hydrogen Sulfide: A Worthwhile Tool in the Design of New Multitarget Drugs. Frontiers in Chemistry, 2017, 5, 72.	3.6	21
49	Oxidative Stress, Mitochondrial Abnormalities and Proteins Deposition: Multitarget Approaches in Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2017, 17, 3062-3079.	2.1	71
50	Synthesis and Functional Evaluation of Novel Aldose Reductase Inhibitors Bearing a Spirobenzopyran Scaffold. Open Medicinal Chemistry Journal, 2017, 11, 9-23.	2.4	2
51	Antiarrhythmic activity of a new spiro-cyclic benzopyran activator of the cardiac mitochondrial ATP dependent potassium channels. Archives of Pharmacal Research, 2016, 39, 1212-1222.	6.3	4
52	Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma. European Journal of Medicinal Chemistry, 2016, 118, 47-63.	5.5	19
53	Hit-to-Lead Optimization of Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists with a Diphenylmethane-Scaffold: Design, Synthesis, and Biological Study. Journal of Medicinal Chemistry, 2016, 59, 9825-9836.	6.4	19
54	Synthesis and In Vivo Imaging of N-(3-[11C]Methoxybenzyl)-2-(3-Methoxyphenyl)ethylaniline as a Potential Targeting Agent for P-glycoprotein. Molecular Imaging and Biology, 2016, 18, 916-923.	2.6	0

#	Article	IF	Citations
55	Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Scientific Reports, 2015, 5, 9956.	3.3	77
56	Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists. Journal of Medicinal Chemistry, 2015, 58, 5096-5107.	6.4	42
57	Synthesis and evaluation of multi-functional NO-donor/insulin-secretagogue derivatives for the treatment of type II diabetes and its cardiovascular complications. Bioorganic and Medicinal Chemistry, 2015, 23, 422-428.	3.0	6
58	Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 807-810.	2.2	56
59	Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme. European Journal of Medicinal Chemistry, 2015, 105, 274-288.	5.5	37
60	Mitochondrial Potassium Channels as Pharmacological Target for Cardioprotective Drugs. Medicinal Research Reviews, 2015, 35, 520-553.	10.5	63
61	SAR study on arylmethyloxyphenyl scaffold: Looking for a P-gp nanomolar affinity. European Journal of Medicinal Chemistry, 2014, 76, 558-566.	5.5	12
62	Arylthioamides as H₂S Donors: <scp>l</scp>-Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo. ACS Medicinal Chemistry Letters, 2013, 4, 904-908.	2.8	144
63	Discovery of novel N-substituted carbazoles as neuroprotective agents with potent anti-oxidative activity. European Journal of Medicinal Chemistry, 2013, 68, 81-88.	5.5	77
64	Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer. ACS Medicinal Chemistry Letters, 2013, 4, 1137-1141.	2.8	24
65	Design, synthesis and pharmacological evaluation of novel tacrineâ€“caffeic acid hybrids as multi-targeted compounds against Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6498-6502.	2.2	90
66	Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase. Steroids, 2012, 77, 212-223.	1.8	26
67	Tacrineâ€6â€Ferulic Acid, a Novel Multifunctional Dimer Against <scp>A</scp>lzheimer's Disease, Prevents Oxidative Stressâ€Induced Neuronal Death Through Activating <scp>N</scp>rf2/<scp>ARE</scp>/<scp>HO</scp>â€1 Pathway in <scp>HT</scp>22 Cells. CNS Neuroscience and Therapeutics, 2012, 18, 950-951.	3.9	26
68	Development of Classification Models for Identifying â€œTrueâ€•P-glycoprotein (P-gp) Inhibitors Through Inhibition, ATPase Activation and Monolayer Efflux Assays. International Journal of Molecular Sciences, 2012, 13, 6924-6943.	4.1	10
69	NO-Releasing Hybrids of Cardiovascular Drugs. , 2012, , 272-308.		0
70	Novel adenosine 5â€²-triphosphate-sensitive potassium channel ligands: a patent overview (2005 â€“ 2010). Expert Opinion on Therapeutic Patents, 2011, 21, 355-379.	5.0	5
71	Editorial [Hot topic: Effect of Stereochemistry in Medicinal Chemistry and Drug Discovery (Guest) Tj ETQq1 1 0.784314 rgBT /Overloc	2.1	2
72	Synthesis and Biological Evaluation of 2â€²â€Oxoâ€2,3â€dihydroâ€3â€²Hâ€• spiro[chromeneâ€4,5â€²â€[1,3]oxazolidin]â€3â€²yl]acetic Acid Derivatives as Aldose Reductase Inhibitors. Archiv Der Pharmazie, 2011, 344, 372-385.	4.1	21

#	Article	IF	Citations
73	Synthesis and biological evaluation of 5-membered spiro heterocycle-benzopyran derivatives against myocardial ischemia. European Journal of Medicinal Chemistry, 2011, 46, 966-973.	5.5	18
74	Evaluation of the NO-releasing properties of NO-donor linkers. Journal of Pharmacy and Pharmacology, 2010, 60, 189-195.	2.4	6
75	Anti-ischemic properties of a new spiro-cyclic benzopyran activator of the cardiac mito-KATP channel. Biochemical Pharmacology, 2010, 79, 39-47.	4.4	35
76	SodiumN-(Methylsulfonyl)-N-(4-nitro-2-phenoxyphenyl)sulfamate: A Water-Soluble Nimesulide Prodrug for Parenteral Use. Molecular Pharmaceutics, 2010, 7, 1871-1876.	4.6	4
77	Predictive models, based on classification algorithms, for compounds potentially active as mitochondrial ATP-sensitive potassium channel openers. Bioorganic and Medicinal Chemistry, 2009, 17, 5565-5571.	3.0	26
78	NO-glibenclamide derivatives: Prototypes of a new class of nitric oxide-releasing anti-diabetic drugs. Bioorganic and Medicinal Chemistry, 2009, 17, 5426-5432.	3.0	28
79	Enantioselectivity in Cardioprotection induced by (S)-(â^')-2,2-Dimethyl-N-(4â€²-acetamido-benzyl)-4-spiromorpholone-chromane. Journal of Medicinal Chemistry, 2009, 52, 1477-1480.	6.4	14
80	Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen Receptor Î². Journal of Medicinal Chemistry, 2009, 52, 858-867.	6.4	38
81	P-gp Transporter and its Role in Neurodegenerative Diseases. Current Topics in Medicinal Chemistry, 2009, 9, 209-217.	2.1	28
82	Î±â€Naphthylaminopropanâ€2â€ol Derivatives as BACE1 Inhibitors. ChemMedChem, 2008, 3, 1530-1534.	3.2	26
83	Synthesis and Biological Evaluation of (Hetero)Arylmethyloxy- and Arylmethylamine-phenyl Derivatives as Potent P-glycoprotein Modulating Agents. Journal of Medicinal Chemistry, 2008, 51, 1415-1422.	6.4	16
84	Spirocyclic Benzopyran-Based Derivatives as New Anti-ischemic Activators of Mitochondrial ATP-Sensitive Potassium Channel. Journal of Medicinal Chemistry, 2008, 51, 6945-6954.	6.4	25
85	2-[(3-Methoxyphenylethyl)phenoxy]-Based ABCB1 Inhibitors: Effect of Different Basic Side-Chains on Their Biological Properties. Journal of Medicinal Chemistry, 2008, 51, 7602-7613.	6.4	19
86	Monoaryl-Substituted Salicylaldoximes as Ligands for Estrogen Receptor Î². Journal of Medicinal Chemistry, 2008, 51, 1344-1351.	6.4	26
87	New Emerging Prospects in the Pharmacotherapy of Hypertension. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2008, 6, 1-19.	1.0	6
88	Synthesis and Affinity Evaluation for AT1 Receptor of Phenylsalicylaldoxime-Derivatives Structurally Related to Sartans. Heterocycles, 2008, 75, 1467.	0.7	4
89	Synthesis and AT1 affinity evaluation of benzamidophenyl analogs of known AT1 receptor ligands with similar aromatic skeleton. Arkivoc, 2008, 2008, 268-286.	0.5	2
90	Cardiac ATP-Sensitive Potassium Channels: A Potential Target for an Anti-Ischaemic Pharmacological Strategy. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 79-90.	1.0	24

#	Article	IF	Citations
91	Synthesis and 5-HT2A, 5-HT1Aand Î±1-Binding Affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-Hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-Hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) Benzyl Oximes. Archiv Der Pharmazie, 2007, 340, 135-139.	4.1	2
92	Arylmethyloxyphenyl Derivatives:â€‰ Small Molecules Displaying P-Glycoprotein Inhibition. Journal of Medicinal Chemistry, 2006, 49, 6607-6613.	6.4	19
93	Proposal of a New Binding Orientation for Non-Peptide AT1 Antagonists:Â Homology Modeling, Docking and Three-Dimensional Quantitative Structureâ^'Activity Relationship Analysis. Journal of Medicinal Chemistry, 2006, 49, 4305-4316.	6.4	72
94	New Benzopyran-Based Openers of the Mitochondrial ATP-Sensitive Potassium Channel with Potent Anti-Ischemic Properties. Journal of Medicinal Chemistry, 2006, 49, 7600-7602.	6.4	46
95	Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes. Journal of Medicinal Chemistry, 2006, 49, 5001-5012.	6.4	27
96	New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite:Â Design, Synthesis, and Biopharmacological Properties. Journal of Medicinal Chemistry, 2006, 49, 2628-2639.	6.4	54
97	Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)-Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase Inhibition. ChemMedChem, 2006, 1, 218-224.	3.2	5
98	NO-Releasing Hybrids of Cardiovascular Drugs. Current Medicinal Chemistry, 2006, 13, 609-625.	2.4	33
99	Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands. Arkivoc, 2006, 2006, 83-94.	0.5	4
100	A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2311-2314.	2.2	23
101	Synthesis of a Resveratrol Analogue with High Ceramide-Mediated Proapoptotic Activity on Human Breast Cancer Cells. Journal of Medicinal Chemistry, 2005, 48, 6783-6786.	6.4	69
102	Variously Substituted (Phosphonoacetamido)Oxy Analogues of Geranylgeranyl Diphosphate (GGdP) as GGdP-transferase (GGTase) Inhibitors and Antiproliferative Agents. Medicinal Chemistry, 2005, 1, 239-244.	1.5	1
103	Synthesis and COX-2 inhibitory properties of N-phenyl- and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene and isoxazole analogs. Il Farmaco, 2004, 59, 25-31.	0.9	33
104	Diaryl-substituted salicyl- and anthranyl-ketoximes as potential estrogen receptor ligands. Il Farmaco, 2004, 59, 601-607.	0.9	2
105	Synthesis and antimicrobial activity of new 7Î²-(benzo[a]dihydrocarbazolyloxyacetyl)-substituted cephalosporins. Il Farmaco, 2004, 59, 691-696.	0.9	4
106	Stable propylphosphonic acid analogues of geranylgeranyl diphosphate possessing inhibitory activity on geranylgeranyl protein transferase. Il Farmaco, 2004, 59, 857-861.	0.9	1
107	Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors. Il Farmaco, 2004, 59, 887-892.	0.9	4
108	Synthesis and Prostaglandin Synthase Inhibitory Activity of New Aromatic O-Alkyloxime Ethers Substituted with Methylsulfonamido or Methylsulfonyl Groups on Their Aliphatic Portion.. ChemInform, 2004, 35, no.	0.0	0

#	Article	IF	Citations
109	Synthesis and COX-2 Inhibitory Properties of N-Phenyl- and N-Benzyl-Substituted Amides of 2-(4-Methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic Acid and of Their Pyrazole, Thiophene and Isoxazole Analogues.. ChemInform, 2004, 35, no.	0.0	1
110	Diaryl-Substituted Salicyl- and Anthranyl-ketoximes as Potential Estrogen Receptor Ligands.. ChemInform, 2004, 35, no.	0.0	0
111	New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorganic and Medicinal Chemistry, 2004, 12, 2441-2450.	3.0	79
112	NO-Sartans:Â A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs. Journal of Medicinal Chemistry, 2004, 47, 5597-5600.	6.4	45
113	Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity. Il Farmaco, 2003, 58, 1277-1281.	0.9	1
114	Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity. Il Farmaco, 2003, 58, 85-89.	0.9	3
115	Ceramide analogues in apoptosis: a new strategy for anticancer drug development. Il Farmaco, 2003, 58, 205-211.	0.9	14
116	Synthesis and prostaglandin synthase inhibitory activity of new aromatic O-alkyloxime ethers substituted with methylsulfonamido or methylsulfonyl groups on their aliphatic portion. Il Farmaco, 2003, 58, 707-714.	0.9	3
117	Ceramide Analogues in Apoptosis: A New Strategy for Anticancer Drug Development. ChemInform, 2003, 34, no.	0.0	0
118	Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4405-4408.	2.2	5
119	Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring. European Journal of Medicinal Chemistry, 2003, 38, 157-168.	5.5	35
120	Synthesis, binding affinity, and transcriptional activity of hydroxy- and methoxy-Substituted 3,4-Diarylsalicylaldoximes on estrogen receptors Î± and Î². Bioorganic and Medicinal Chemistry, 2003, 11, 1247-1257.	3.0	29
121	Novel Estrogen Receptor Ligands Based on an Anthranylaldoxime Structure:Â Role of the Phenol-Type Pseudocycle in the Binding Process. Journal of Medicinal Chemistry, 2003, 46, 4032-4042.	6.4	20
122	Synthesis, Antifungal Activity, and Molecular Modeling Studies of New Inverted Oxime Ethers of Oxiconazole. Journal of Medicinal Chemistry, 2002, 45, 4903-4912.	6.4	111
123	(E)-[2-(4-Methylsulphonylphenyl)-1-cyclopentenyl-1-methyliden](arylmethyloxy)amines. Methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: synthesis and biological properties. European Journal of Medicinal Chemistry, 2002, 37, 391-398.	5.5	13
124	Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties. European Journal of Medicinal Chemistry, 2002, 37, 585-594.	5.5	6
125	Synthesis and inhibitory activity towards human leukocyte elastase of new 7Î±-methoxy and 7Î±-chloro (2-acyloxymethyl) cephem derivatives. European Journal of Medicinal Chemistry, 2001, 36, 185-193.	5.5	6
126	Enantiopure 3-(arylmethylidene)aminoxy-2-methylpropionic acids: synthesis and antiinflammatory properties. European Journal of Medicinal Chemistry, 2001, 36, 799-807.	5.5	8

#	Article	IF	Citations
127	Endogenous TH metabolite 3-iodothyronamine (T1AM) and synthetic thyronamine-like analogues SG-1 and SG-2 induce autophagy in human glioblastoma cells (U-87MG). Endocrine Abstracts, 0, , .	0.0	0